HARMONY BIOSCIENCES ($HRMY) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of $0.38 per share, missing estimates of $0.91 by $0.53. The company also reported revenue of $243,780,000, missing estimates of $245,193,536 by $-1,413,536.
You can see Quiver Quantitative's $HRMY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HARMONY BIOSCIENCES Insider Trading Activity
HARMONY BIOSCIENCES insiders have traded $HRMY stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HRMY stock by insiders over the last 6 months:
- SANDIP KAPADIA (CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 48,134 shares for an estimated $1,802,845.
- JEFFREY M. DAYNO (PRESIDENT, CEO) has made 0 purchases and 2 sales selling 25,933 shares for an estimated $1,040,102.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HARMONY BIOSCIENCES Hedge Fund Activity
We have seen 167 institutional investors add shares of HARMONY BIOSCIENCES stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VALOR MANAGEMENT LLC removed 1,151,074 shares (-90.8%) from their portfolio in Q4 2025, for an estimated $43,073,189
- SG AMERICAS SECURITIES, LLC added 938,783 shares (+4102.4%) to their portfolio in Q4 2025, for an estimated $35,129,259
- FMR LLC removed 734,160 shares (-19.1%) from their portfolio in Q4 2025, for an estimated $27,472,267
- ARMISTICE CAPITAL, LLC added 500,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,710,000
- AQR CAPITAL MANAGEMENT LLC added 458,321 shares (+128.9%) to their portfolio in Q4 2025, for an estimated $17,150,371
- PACER ADVISORS, INC. removed 362,948 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,581,514
- CITADEL ADVISORS LLC added 352,398 shares (+518.1%) to their portfolio in Q4 2025, for an estimated $13,186,733
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HARMONY BIOSCIENCES Government Contracts
We have seen $883,113 of award payments to $HRMY over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BULK - WAKIX 17.8MG TAB: $619,879
- BULK WAKIX: $39,243
- WAKIX 17.8 MG: $10,418
- WAKIX 17.8 MG: $10,418
- WAKIX 17.8 MG: $10,418
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
HARMONY BIOSCIENCES Analyst Ratings
Wall Street analysts have issued reports on $HRMY in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/08/2026
- Mizuho issued a "Outperform" rating on 12/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Needham issued a "Buy" rating on 11/24/2025
- Deutsche Bank issued a "Buy" rating on 09/25/2025
To track analyst ratings and price targets for HARMONY BIOSCIENCES, check out Quiver Quantitative's $HRMY forecast page.
HARMONY BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $HRMY recently. We have seen 6 analysts offer price targets for $HRMY in the last 6 months, with a median target of $45.5.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $46.0 on 02/11/2026
- Danielle Brill from Truist Securities set a target price of $45.0 on 01/08/2026
- Graig Suvannavejh from Mizuho set a target price of $46.0 on 12/01/2025
- Ami Fadia from Needham set a target price of $42.0 on 11/24/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $55.0 on 11/24/2025
- David Hoang from Deutsche Bank set a target price of $36.0 on 09/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
